Anti-Aging · Reference
FOXO4-DRI for Women: What Research Has Looked At, and What to Check First
This page covers what FOXO4-DRI is, what research has and has not looked at that is relevant to women, the considerations that change for women, and how Pepti supplies it. For the general evidence, benefit by benefit, see FOXO4-DRI benefits; for the product reference, what is FOXO4-DRI.
Treatments mentioned
No study has looked at FOXO4-DRI in women specifically, and no study has given it to any person, woman or man. The research is mouse work and human cells studied in a dish, including a 2025 study of senescent fibroblasts in human keloid scar tissue and a 2021 study of human cartilage cells, and none of it reports separate results for women. FOXO4-DRI is not used in pregnancy or while breastfeeding, because safety data is absent, and it is not a menopause or hormone treatment. Compounded FOXO4-DRI is a prescription injection and is not FDA approved.
This page covers what FOXO4-DRI is, what research has and has not looked at that is relevant to women, the considerations that change for women, and how Pepti supplies it. For the general evidence, benefit by benefit, see FOXO4-DRI benefits; for the product reference, what is FOXO4-DRI.
FOXO4-DRI for Women
The short answer
| Question | What the live research shows | Strength of evidence |
|---|---|---|
| Has FOXO4-DRI been studied in women? | No. No study of women, and no human treatment study of anyone | None |
| Does it help skin or scarring? | Human keloid tissue studied after removal: FOXO4-DRI induced apoptosis of senescent fibroblasts (Communications Biology, 2025) | Human tissue in a dish, not treatment |
| Does it reverse aging? | Restored fitness, fur density and kidney function in aged mice (Cell, 2017) | Mouse only |
| Does it help menopause symptoms? | Not studied; FOXO4-DRI is not hormone therapy | None |
| Is it used in pregnancy or breastfeeding? | No; safety data is absent | Clear exclusion |
| Is there female-specific animal work? | The tissue-specific mouse studies in the live research are on male Leydig cells; none is on the female reproductive system | None |
The honest summary: nothing specific to women, and nothing in people of either sex beyond tissue and cells in a dish.
FOXO4-DRI for Women
What FOXO4-DRI is, in one paragraph
FOXO4-DRI is a designed peptide described in a 2017 paper in Cell from the laboratory of Peter de Keizer at Erasmus University Medical Center in Rotterdam. It targets senescent cells: cells that have permanently stopped dividing but have not died, and that secrete inflammatory signals into the tissue around them. In those cells a transcription factor called FOXO4 holds p53 in the nucleus and keeps it from triggering the cell's own death programme. FOXO4-DRI copies a stretch of FOXO4 and acts as a decoy, and in mouse and cell studies the senescent cell then undergoes apoptosis. "DRI" means D-retro-inverso, mirror-image amino acids assembled in reverse, which lets it resist breakdown. It does not act on estrogen, progesterone or any part of the reproductive axis.
FOXO4-DRI for Women
What research has looked at that is relevant to women
Skin and scar tissue
This is the research closest to the reasons women usually ask. A 2025 paper in Communications Biology described senescent fibroblasts in human keloid tissue, the raised overgrowth of scar some people form after injury, and reported that FOXO4-DRI induced their apoptosis in keloid organ cultures and cell models. A 2023 paper in Naunyn-Schmiedeberg's Archives of Pharmacology reported less collagen deposition in a mouse model of lung fibrosis and described the peptide reducing extracellular matrix production in activated fibroblasts.
What it shows. That in human scar tissue removed from the body, and in mouse fibrosis, FOXO4-DRI acted on senescent fibroblasts.
What it does not show. Any effect on skin, wrinkles, scars or appearance when injected into a person. Tissue studied in a dish after removal is a different thing from treating someone. If skin is the priority, GHK-Cu is aimed at it more directly.
Cartilage cells
A 2021 study in Frontiers in Bioengineering and Biotechnology used human chondrocytes, cartilage cells, expanded in a dish for autologous cartilage implantation. Senescence builds up during that expansion, and FOXO4-DRI selectively removed the senescent fraction while sparing the rest. This is a laboratory finding about cells grown for a surgical procedure, not evidence about joints in a living person.
The mouse aging studies
The 2017 Cell paper reported that FOXO4-DRI neutralised chemotherapy-induced toxicity in mice and restored running-wheel activity, fur density and kidney function in fast-aging and naturally old mice after a short course of intraperitoneal injection. A 2026 paper reported reduced aortic aging markers in aged mice. None of these is described as reporting separate findings by sex.
What is missing
The two tissue-specific reproductive studies in the FOXO4-DRI literature, in Aging (2020) and Experimental Gerontology (2024), are on male Leydig cells, testosterone and sperm. There is no equivalent work on ovaries, the menstrual cycle, bone after menopause or any other female-specific question in the live research. Anyone describing FOXO4-DRI as a women's longevity or hormone treatment is describing something that has not been studied.
FOXO4-DRI for Women
What changes for women
Pregnancy and breastfeeding
FOXO4-DRI is not used in pregnancy or while breastfeeding. There is no human safety data of any kind, and the compound acts on p53, which is central to how cells respond to damage. If you are trying to conceive, tell your physician before starting. If you become pregnant on treatment, stop and contact your physician the same day. Can you take peptides while pregnant covers the detail, and do peptides affect fertility covers trying to conceive.
Perimenopause and menopause
Fatigue, poor sleep, skin changes and low mood in the forties and fifties are often the menopausal transition itself. FOXO4-DRI is not hormone therapy, does not act on the hormones that change, and has not been tested for hot flashes, sleep, bone or any menopause outcome. If the transition is the driver, it belongs in the conversation with your physician rather than being treated around. The wider picture is in peptides for menopause and peptides for women.
Contraception and the cycle
FOXO4-DRI is not a hormone and is not described as affecting the cycle or hormonal contraception. No study has looked at that directly, so any cycle change on treatment is worth reporting, even if another cause is likelier.
Cancer history
Senescence is one of the body's defences against cancer, and FOXO4-DRI acts on p53, the central tumour-suppressor protein. Nobody has studied what that means over time in people. A personal or family history of breast, ovarian, endometrial or any other cancer goes on the intake in full and is a reason to discuss FOXO4-DRI carefully before anything is prescribed. More is in can peptides cause cancer.
Lungs
A 2023 mouse study in Circulation reported that eliminating senescent cells in the pulmonary vessels with senolytic interventions worsened pulmonary hypertension. It has not been shown in people, but pulmonary hypertension or significant lung disease should be raised at intake.
FOXO4-DRI for Women
What the evidence does not establish
- That FOXO4-DRI changes skin, scarring, energy, weight, hormones or aging in women. Those studies have not been done.
- That it clears senescent cells in any living person.
- Any effect on menopause symptoms, bone density or the cycle.
- A human dose, schedule or route. The mouse work used short courses of intraperitoneal injection.
- Human safety, short-term or long-term, in either sex.
FOXO4-DRI for Women
Side effects and considerations
Nothing in the live research suggests the picture differs between women and men.
| What is reported or relevant | What to do |
|---|---|
| Injection-site redness, mild soreness, occasional bruising | Rotate sites between abdomen and thigh |
| Immune reactions to the peptide's unusual chemistry | A theoretical concern, not studied in people; report a rash or hives away from the site |
| Pregnancy, trying to conceive or breastfeeding | Not used; tell your physician |
| Cancer history, personal or family | Put it on the intake |
| Facial or throat swelling, widespread rash, difficulty breathing | Call 911 first, then tell your physician |
There is no established interaction list. List every medication you take, including contraception and any hormone therapy, so your physician can review them together.
FOXO4-DRI for Women
Where FOXO4-DRI stands with the FDA
FOXO4-DRI does not appear in Category 1, 2 or 3 of the FDA's 503A nominated-substances document updated 14 May 2026, is not on the FDA's significant-safety-risk page, is not on the 503A bulks list, and was not on the agenda of the Pharmacy Compounding Advisory Committee's July 2026 meeting or the one announced for early 2027. The FDA has not evaluated it either way. Compounded FOXO4-DRI is not FDA approved. Women who compete in a tested sport should read is FOXO4-DRI banned in sports first.
FOXO4-DRI for Women
How Pepti supplies FOXO4-DRI
| Product | What is in it | Typical directions | Price |
|---|---|---|---|
| FOXO4-DRI | 5 mL multi-dose vial, 2 mg/mL (10 mg FOXO4-DRI) | 0.25 mL (25 units) subcutaneously once daily Monday through Friday; 0.5 mg per dose (math only), 20 doses, about 4 weeks | $229/mo |
| GHK-Cu | 5 mL multi-dose vial, 10 mg/mL (50 mg GHK-Cu) | A separate product, aimed at skin and connective tissue | $239/mo |
| NAD+ Injection | 10 mL multi-dose vial, 100 mg/mL (1000 mg NAD+) | A separate anti-aging product with precursor trials in people | $249/mo |
Refills run every 28 days, one vial per fill. Prescribers generally treat FOXO4-DRI as an intermittent course, so whether a further vial follows is reviewed each time. Your physician sets your directions after reviewing your intake, and they are printed on the vial. The unit chart is in FOXO4-DRI dosage, and NAD+ for women is covered in NAD+ for women.
Every price is all-in, covering medication, physician review, refill management and shipping, with no membership fee. Pepti is cash-pay and does not bill insurance. Vials arrive as solutions ready to use, with sterile syringes and alcohol prep pads, shipped refrigerated with ice packs.
FOXO4-DRI for Women
Where to get FOXO4-DRI prescribed
FOXO4-DRI cannot be bought legitimately without a prescription. Sites selling it "for research use only" are not accountable for identity, purity, sterility or concentration. The prescription route:
- Complete a free online intake covering your history, medications, pregnancy and contraception status, and what you want help with.
- A physician licensed in your state reviews it, usually within 24 hours.
- If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
- It ships refrigerated with your directions printed on the vial.
- Your physician stays reachable for questions and side effects.
Pepti prescribes in most US states, not currently in Oklahoma, and the assessment confirms availability for your state. Step by step: how to get FOXO4-DRI prescribed online. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.
References
What this is based on.
References
- Baar MP, Brandt RMC, Putavet DA et al.. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging · Cell (2017) · PMID 28340339
- Bourgeois B, Spreitzer E, Platero-Rochart D et al.. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI · Nature Communications (2025) · PMID 40593617
- Zhang C, Xie Y, Chen H et al.. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice · Aging (Albany NY) (2020) · PMID 31959736
- Huang Y, He Y, Makarcyzk MJ et al.. Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes · Frontiers in Bioengineering and Biotechnology (2021) · PMID 33996787
- Liu Y, Hou Q, Wang R et al.. FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice · Naunyn-Schmiedeberg's Archives of Pharmacology (2023) · PMID 37074394
- Li Y, Zhang C, Cheng H et al.. FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells · Experimental Gerontology (2024) · PMID 39025385
- Hu Z, Li F, Hu C et al.. FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway · Frontiers in Bioengineering and Biotechnology (2026) · PMID 41625068
- Kong YX, Li ZS, Liu YB et al.. FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation · Communications Biology (2025) · PMID 39994346
- Born E, Lipskaia L, Breau M et al.. Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression · Circulation (2023) · PMID 36515093
Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.
Common questions
FOXO4-DRI for Women, answered.
No study has looked at it in women, and no study has treated any person with it. The research is in mice and in human cells or tissue studied in a dish, with no separate results for women.
Not studied in people. A 2025 study reported that FOXO4-DRI induced apoptosis of senescent fibroblasts in human keloid tissue studied after removal. That is not evidence of any effect on skin when injected.
It has not been tested for any menopause symptom. It is not hormone therapy and does not act on estrogen or progesterone. See peptides for menopause.
No. It is not used in either situation because safety data is absent. If you become pregnant on treatment, stop and contact your physician the same day.
Tell your physician before starting. There is no human safety data, and the usual approach is not to start an experimental injectable while actively trying.
It is not a hormone and is not described as acting on the reproductive axis. No study has looked at cycle effects, so report any change to your physician.
No interaction has been described, but no study has looked at either combination. List both on your intake so your physician can review them together.
The same as for men: mostly injection-site redness, soreness or bruising, with no published human safety data. A history of cancer or lung disease should be discussed first.
It is an experimental senolytic. The aging findings are in mice, and nothing shows it changes aging, lifespan or healthspan in women or men.
At Pepti, $229 a month all-in, covering medication, physician review, refill management and shipping.
No. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account. The free assessment goes to a physician licensed in your state. A consultation does not guarantee a prescription.
Next step
See what a physician recommends for you.
A licensed physician in your state reviews your intake and decides what is appropriate. A consultation does not guarantee a prescription.